Nwam LLC Raises Stake in Insmed, Inc. (NASDAQ:INSM)

Nwam LLC boosted its position in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 49.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 53,789 shares of the biopharmaceutical company's stock after buying an additional 17,693 shares during the quarter. Nwam LLC's holdings in Insmed were worth $4,104,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Insmed by 6.3% in the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock valued at $1,257,838,000 after buying an additional 1,075,796 shares in the last quarter. Darwin Global Management Ltd. increased its position in shares of Insmed by 23.5% in the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock valued at $894,796,000 after buying an additional 2,463,261 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Insmed by 1.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,704,410 shares of the biopharmaceutical company's stock valued at $877,113,000 after buying an additional 123,429 shares in the last quarter. Capital International Investors increased its position in shares of Insmed by 9.1% in the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock valued at $491,357,000 after buying an additional 593,206 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Insmed by 7.2% in the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock valued at $282,243,000 after buying an additional 273,759 shares in the last quarter.

Analyst Ratings Changes

A number of equities analysts have issued reports on INSM shares. Leerink Partners increased their target price on Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a report on Tuesday, June 10th. Wells Fargo & Company raised their price objective on shares of Insmed from $107.00 to $119.00 and gave the stock an "overweight" rating in a research report on Wednesday, June 11th. UBS Group reduced their target price on Insmed from $110.00 to $109.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Jefferies Financial Group restated a "buy" rating on shares of Insmed in a research report on Tuesday, June 10th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Insmed from $90.00 to $111.00 and gave the stock an "overweight" rating in a report on Tuesday, July 8th. One equities research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $108.47.

Insmed Stock Performance

INSM traded down $1.61 during midday trading on Friday, reaching $102.56. The company had a trading volume of 1,432,373 shares, compared to its average volume of 2,296,715. The company has a debt-to-equity ratio of 11.38, a quick ratio of 5.44 and a current ratio of 5.86. The stock has a market cap of $19.46 billion, a PE ratio of -17.24 and a beta of 0.90. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $106.83. The business has a 50-day moving average price of $86.93 and a two-hundred day moving average price of $78.50.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). The business had revenue of $92.82 million for the quarter, compared to analysts' expectations of $91.63 million. Insmed had a negative net margin of 265.93% and a negative return on equity of 446.98%. The business's quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.06) earnings per share. On average, sell-side analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Insmed

In related news, Director David W. J. Mcgirr sold 3,000 shares of the company's stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $73.27, for a total transaction of $219,810.00. Following the sale, the director owned 97,723 shares of the company's stock, valued at approximately $7,160,164.21. This represents a 2.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Sara Bonstein sold 57,764 shares of the stock in a transaction on Monday, July 7th. The stock was sold at an average price of $95.86, for a total transaction of $5,537,257.04. Following the completion of the transaction, the chief financial officer directly owned 84,017 shares in the company, valued at $8,053,869.62. The trade was a 40.74% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 548,197 shares of company stock worth $49,124,834 in the last ninety days. Insiders own 3.00% of the company's stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.